# First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors

> **NCT04746612** · PHASE1 · TERMINATED · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HH30134

## Key facts

- **NCT ID:** NCT04746612
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-08
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-03-24
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Sponsor business decision
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04746612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04746612, "First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04746612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*